沃森生物：关于子公司收到13价肺炎结合疫苗埃及上市许可证的公告

Core Viewpoint - Watson Bio's subsidiary, Yuxi Watson Bio, has received marketing authorization for its 13-valent pneumococcal polysaccharide conjugate vaccine from the Egyptian Drug Authority, marking a significant milestone for the company in expanding its product offerings in international markets [1] Group 1 - The 13-valent pneumococcal conjugate vaccine has been granted a marketing license in Egypt [1] - This approval signifies the company's efforts to penetrate the international vaccine market [1] - The vaccine's entry into Egypt may enhance the company's revenue potential and market presence [1]